Impact of Erythropoietin on Anemia in End-Stage Renal Disease
Patients on Hemodialysis
الباحث الأول:
Bashaer M. Muhammad-Baqir,
الباحثين الآخرين:
Evan Noori Hameed, Rawaa Hadi Shareef1, Mustafa H. Ahmed2
المجلة:
Medical Journal of Babylon
تاريخ النشر:
27 سبتمبر، 2023
مختصر البحث:
Background: End-stage kidney disease occurs when the estimated glomerular filtration rate is not more than 15 mL/min/1.73 m2 or
when the patient requires long-term renal replacement therapy regardless of estimated glomerular filtration rate. Anemia…
Background: End-stage kidney disease occurs when the estimated glomerular filtration rate is not more than 15 mL/min/1.73 m2 or
when the patient requires long-term renal replacement therapy regardless of estimated glomerular filtration rate. Anemia is observed
as a frequent comorbid complication of chronic kidney disease (CKD). Erythropoietin (EPO) deficiency is the crucial cause of CKDanemia
development. Objectives: The aim of study was to determine the impact of EPO on anemia in end-stage renal disease patients
on hemodialysis (HD). Materials and Methods: This study was a cross-sectional study. A total of 80 patients (42 men and 38women)
at end-stage renal disease planned for HD program at Al-Hakeem general hospital in Al-Najaf city/Iraq in period between November
2020 and February 2021. Many information and analyses were taken such as age, sex, cause of end stage, blood urea, serum creatinine
and albumin, hemoglobin, dose of EPO, blood pressure, and body weight. Results: The results of study showed that, the level of
hemoglobin (g/dL) significantly increased from (8.24 ± 1.77) to (9.57 ± 1.35) after treatment with EPO (P value < 0.05), whereas the
levels of blood urea (mg/dL), albumin (g/L) significantly decreased from (218.51 ± 74.47) to (145.76 ± 42.47) and from (40.65 ± 6.35)
to (36.56 ± 6.03) respectively, after treatment with EPO (P value < 0.05). additionally, there are no significant differences in serum
creatinine (mg/dL) and blood pressure after treatment with EPO. Conclusion: EPO has a positive role on renal function and in treating
anemia in end-stage renal disease patients on HD.
